NEW YORK (GenomeWeb News) - Gene Network Sciences will use its biological modeling software to assist CombinatoRx in drug efficacy and safety studies, GNS said last week.
Under the agreement, the companies will use GNS' reverse engineering/forward simulation software, which it calls REFSTM, to characterize the cellular mechanisms that can cause “synergistic interactions” between multi-target candidate drugs.
REFSTM will use data from CombinatoRx’s protein expression and transcriptional profiling studies to create models that simulate both the mechanisms of disease and clinical performance in drug candidates, GNS said.
Financial terms of the agreement were not released.